Immunovant Inc (IMVT) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Immunovant Inc (IMVT) following the 2026 Q2 hedge fund 13F filings?

As of today, IMVT has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), IMVT gained +8.5% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Immunovant Inc (IMVT)

210 + Investors. Track Smart Money conviction in IMVT. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — IMVT

Based on 212 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added IMVT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (95% of max)

95% of all-time peak

212 hedge funds hold IMVT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +7% more funds vs a year ago

fund count last 6Q

+14 new funds entered over the past year (+7% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction. The peak was reached in just 2 quarters from the low — a sharp move.

🟢

More buyers than sellers — 66% buying

140 buying72 selling

Last quarter: 140 funds were net buyers (43 opened a brand new position + 97 added to an existing one). Only 72 were sellers (45 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.

➡️

Steady new buyers — ~43 new funds per quarter

new funds entering per quarter

Funds opening this position for the first time: 23 → 31 → 41 → 43. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.

🔒

53% of holders stayed for 2+ years

■ 53% conviction (2yr+) ■ 27% medium ■ 20% new

112 out of 212 hedge funds have held IMVT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

🚀

Acceleration phase — new buyers rushing in

39 → 23 → 31 → 41 → 43 new funds/Q

New funds entering each quarter: 23 → 31 → 41 → 43. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🏛️

Veteran-anchored — 65% veterans vs 24% newcomers

■ 65% veterans ■ 11% 1-2yr ■ 24% new

Entry-cohort mix of 223 holders: 145 (65%) are 2+ year veterans, 24 entered 1–2 years ago, and 54 (24%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds

43 of 211 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in IMVT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

3.5

out of 10

Low Exit Risk

Exit risk score 3.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	210	196	7.14%
13F Shares	113M	106M	7.23%
Total Value	$2.70B	$2.66B	1.67%
New Positions	41	41	-
Increased Positions	92	76	+16
Closed Positions	27	29	-2
Reduced Positions	43	54	-11
Total Calls	6	8	-25.0%
Total Puts	6	6	-
PUT/CALL Ratio	1.0	0.75	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

210

196

7.14%

13F Shares

113M

106M

7.23%

Total Value

$2.70B

$2.66B

1.67%

New Positions

Increased Positions

+16

Closed Positions

-2

Reduced Positions

-11

Total Calls

-25.0%

Total Puts

PUT/CALL Ratio

1.0

0.75

Neutral

Institutional Holders (2026 Q2)

210 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IMVT. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 IMVT holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Alpine Global Management, LLC	8.61%	1,375,000	$53.0M
2	Deep Track Capital, LP	5.24%	9,341,151	$359.9M
3	Superstring Capital Management LP	5.07%	208,368	$8.0M
4	TCG Crossover Management, LLC	4.13%	4,457,988	$171.8M
5	ADAR1 Capital Management, LLC	4.11%	2,330,716	$89.8M
6	Silverarc Capital Management, LLC	2.48%	619,096	$23.9M
7	HighVista Strategies LLC	2.44%	277,873	$10.7M
8	Two Seas Capital LP	2.40%	3,148,505	$121.3M
9	Stempoint Capital LP	1.84%	276,527	$10.7M
10	Tetragon Partners GP Ltd	1.55%	255,934	$9.9M
11	Platinum Investment Management Ltd	1.37%	144,671	$5.6M
12	Logos Global Management LP	1.10%	665,000	$25.6M
13	DAFNA Capital Management LLC	1.10%	149,524	$5.8M
14	Baker BROS. Advisors LP	1.05%	5,435,220	$209.4M
15	Rtw Investments, LP	1.05%	3,177,849	$122.4M
16	Alchemi Wealth, LLC	0.84%	46,500	$1.8M
17	Armistice Capital, LLC	0.82%	1,736,000	$66.9M
18	Perceptive Advisors LLC	0.79%	1,357,383	$52.3M
19	Armistice Capital, LLC	0.57%	1,200,000	$46.2M
20	Informed Momentum Co LLC	0.44%	127,273	$4.9M
21	Soleus Capital Management, L.P.	0.33%	252,000	$9.7M
22	Granahan Investment Management, LLC	0.28%	206,372	$8.0M
23	PSP Research LLC	0.27%	13,000	$501K
24	Atom Investors LP	0.25%	74,171	$2.9M
25	Woodline Partners LP	0.24%	1,975,869	$76.1M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Immunovant Inc (IMVT)

What does the Smart Money Trend signal show for IMVT?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added IMVT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IMVT?

More buyers than sellers — 66% buying: Last quarter: 140 funds were net buyers (43 opened a brand new position + 97 added to an existing one). Only 72 were sellers (45 trimmed + 27 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for IMVT holders?

Elite ownership — 42% AUM from top-100 funds: 43 of 211 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in IMVT. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held IMVT?

53% of holders stayed for 2+ years: 112 out of 212 hedge funds have held IMVT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Immunovant Inc (IMVT) following the 2026 Q2 hedge fund 13F filings?

As of today, IMVT has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), IMVT has gained +8.5% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Immunovant Inc (IMVT)

Smart Money Signals — IMVT

Buying streak — 3 quarters in a row

At the ownership peak (95% of max)

Steady growth — +7% more funds vs a year ago

More buyers than sellers — 66% buying

Steady new buyers — ~43 new funds per quarter

53% of holders stayed for 2+ years

Acceleration phase — new buyers rushing in

Veteran-anchored — 65% veterans vs 24% newcomers

Elite ownership — 42% AUM from top-100 funds

Institutional Sentiment Summary — IMVT

Hedge Fund Ownership: IMVT

Market Analysis: IMVT

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: IMVT

Is It Too Late to Buy Immunovant Inc (IMVT) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: IMVT

Statistics: IMVT

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Immunovant Inc (IMVT)

Welcome to 13Foresight!